NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announces participation in three upcoming investor conferences to present their late-stage, clinical biopharmaceutical developments for cardiovascular disease. Live webcasts and archived replays will be available for investors.

NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in three upcoming investor conferences:

• TD Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024. Michael Davidson, Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 2:10 p.m. ET.
• Leerink Global Biopharma Conference in Miami, FL on Monday, March 11, 2024. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 4:00 p.m. ET.
• Jefferies Biotech on the Bay Summit in Miami, FL on Tuesday, March 12, 2024. Company management will be available for 1x1 meetings throughout the day.
  
  

Live webcasts of both the Cowen and Leerink presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Jen Gordon
P: 1-202-957-7795
jgordon@spectrumscience.com

Investor Contact
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1-212-362-1200
hannah.deresiewicz@sternir.com

FAQ

When will NewAmsterdam Pharma Company N.V. participate in the TD Cowen 44th Annual Health Care Conference?

NewAmsterdam Pharma Company N.V. will participate in the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, in Boston, MA.

Who will present a corporate overview at the Leerink Global Biopharma Conference?

Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at the Leerink Global Biopharma Conference on Monday, March 11, 2024, in Miami, FL.

Where can investors watch the live webcasts of the Cowen and Leerink presentations?

Investors can watch the live webcasts of the Cowen and Leerink presentations through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com.

What type of medicines is NewAmsterdam Pharma Company N.V. developing?

NewAmsterdam Pharma Company N.V. is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.

Why is NewAmsterdam Pharma Company N.V. participating in these investor conferences?

NewAmsterdam Pharma Company N.V. is participating in these investor conferences to present their late-stage, clinical biopharmaceutical developments for cardiovascular disease to potential investors and stakeholders.